Early preclinical data in intrahepatic cholangiocarcinoma in particular suggests that bromodomain and extraterminal domain (BET) (histone regulatory complexes) inhibitors such as JQ1 may have an enhanced antiproliferative effect in IDH-mutant cancer cell lines (130). The gene discussed is IDH1; the disease is cancer.